8-K: Cara Therapeutics Announces First Quarter 2024 Financial Results and Provides Clinical Program Update

Cara Therapeutics reported its first quarter 2024 financial results and announced that topline efficacy and safety results from the KOURAGE 1 Part A study are expected by the end of the second quarter of 2024.

Summary

• Cara Therapeutics announced its financial results for the first quarter of 2024, reporting a net loss of $30.7 million, or $(0.56) per share, compared to a net loss of $26.7 million, or ($0.49) per share, for the same period in 2023.
• Total revenue for the quarter was $2.1 million, down from $6.2 million in the first quarter of 2023, primarily due to lower collaborative and commercial supply revenue related to KORSUVA injection.
• The company's cash, cash equivalents, and marketable securities totaled $69.8 million as of March 31, 2024, a decrease from $100.8 million at the end of 2023, mainly due to $30.5 million used in operating activities.
• Research and development expenses decreased to $22.0 million from $24.3 million in the same period of 2023, due to reduced costs in certain programs, partially offset by increased spending on the oral difelikefalin NP program.
• The company expects topline efficacy and safety results from the KOURAGE 1 Part A study by the end of the second quarter of 2024, with final results from the first pivotal study expected by the end of 2025 and the second pivotal study results in early 2026.
• KORSUVA injection generated net sales of approximately $1.8 million in the first quarter of 2024, with collaborative revenue of approximately $800,000 representing the company's share of the profit from sales.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the clinical program is progressing, the financial results show a significant loss and a decrease in revenue. The company's cash runway is positive, but the high cash burn rate is a concern.

Positives

• The KOURAGE 1 Part A study is progressing ahead of schedule, with topline results expected by the end of the second quarter of 2024.
• The company's cash runway is expected to extend into 2026.
• The medical dermatology community's interest in the clinical program highlights the unmet need for effective NP treatments.
• The company is advancing its Phase 2/3 program for oral difelikefalin in notalgia paresthetica.

Negatives

• The company experienced a net loss of $30.7 million in the first quarter of 2024, an increase from $26.7 million in the same period of 2023.
• Total revenue decreased to $2.1 million in the first quarter of 2024, down from $6.2 million in the first quarter of 2023.
• Cash, cash equivalents, and marketable securities decreased from $100.8 million at the end of 2023 to $69.8 million as of March 31, 2024.
• The company incurred $2.4 million in restructuring expenses related to the strategic prioritization of NP and associated workforce reduction.

Risks

• The company's future results are subject to risks and uncertainties, including the success of clinical trials and regulatory approvals.
• The company's cash runway is dependent on the success of its clinical programs and the ability to manage costs.
• The company's revenue is dependent on the sales of KORSUVA injection, which is subject to market conditions and competition.
• The company's restructuring activities may impact its operations and financial performance.

Future Outlook

Cara Therapeutics expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund its currently anticipated operating plan into 2026.

Management Comments

• Christopher Posner, President and Chief Executive Officer of Cara Therapeutics, stated that the NP pivotal clinical program is progressing ahead of schedule.
• Mr. Posner also noted the medical dermatology community's interest in the clinical program, underscoring the significant unmet need for an effective and safe anti-pruritic treatment for the sizeable NP patient population.

Industry Context

The announcement highlights the ongoing efforts in the biopharmaceutical industry to develop treatments for pruritus, particularly in underserved areas like notalgia paresthetica. The company's focus on oral difelikefalin represents a potential advancement in the treatment of this condition.

Comparison to Industry Standards

• Cara Therapeutics' revenue is significantly lower than established pharmaceutical companies with marketed products, such as CSL Vifor, which is their partner for KORSUVA.
• The company's R&D spending is typical for a development-stage biopharmaceutical company, but lower than larger companies with broader pipelines.
• The company's cash burn rate is a concern, as it is losing approximately $30 million per quarter, which is not unusual for a company in this stage of development.
• The company's focus on notalgia paresthetica is a niche area, and there are no direct comparables in terms of companies with approved therapies for this specific condition.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue.
• Employees may be affected by the restructuring and workforce reduction.
• Patients with notalgia paresthetica may benefit from the potential development of oral difelikefalin.
• CSL Vifor, the company's partner for KORSUVA, is impacted by the sales performance of the product.

Next Steps

• The company will report topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024.
• The company will continue to advance the Phase 2/3 program of oral difelikefalin in notalgia paresthetica.
• The company will initiate the Phase 3 pivotal portion of the KOURAGE program.

Key Dates

Keywords

Cara Therapeutics, difelikefalin, KORSUVA, notalgia paresthetica, pruritus, clinical trials, biopharmaceutical, financial results, KOURAGE, revenue